High‐dose PPI‐amoxicillin dual therapy with or without bismuth for first‐line Helicobacter pylori therapy: A randomized trial

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency

(2018) David Y. Graham et al.   Clinical Gastroenterology and Hepatology

Tu1299 - Vonoprazan-Based Dual Therapy with Amoxicillin is as Effectve as the Triple Therapy for the Eradication of H. Pylori

(2018) Takahisa Furuta et al.   GASTROENTEROLOGY

Update on the Use of Vonoprazan: A Competitive Acid Blocker

(2018) David Y. Graham et al.   GASTROENTEROLOGY

Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies

(2018) David Y. Graham et al.   Expert Review of Anti-Infective Therapy

Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI

(2018) David Y. Graham et al.   HELICOBACTER

Optimized high-dose amoxicillin–proton-pump inhibitor dual therapies fail to achieve high cure rates in China

(2017) Dian-Chun Fang et al.   Saudi Journal of Gastroenterology

Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now?

(2017) DavidY Graham et al.   Saudi Journal of Gastroenterology

Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report

(2016) P Malfertheiner et al.   GUT

Role of bismuth in improvingHelicobacter pylorieradication with triple therapy

(2016) Maria Pina Dore et al.   GUT

High Dose Ilaprazole/Amoxicillin as First-Line Regimen forHelicobacter pyloriInfection in Korea

(2016) WonGun Kwack et al.   Gastroenterology Research and Practice

Colloidal bismuth subcitrate impedes proton entry intoHelicobacter pyloriand increases the efficacy of growth-dependent antibiotics

(2015) E. A. Marcus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole

(2014) S. Sahara et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

High-Dose Extended-Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy forHelicobacter pyloriInfections

(2014) Taraq A. Attumi et al.   HELICOBACTER

New dual therapy for primary treatment ofHelicobacter pyloriinfection: A prospective randomized study in Shanghai, China

(2014) Ling Ren et al.   Journal of Digestive Diseases

Effect of dosing schemes of amoxicillin on eradication rates ofHelicobacter pyloriwith amoxicillin-based triple therapy

(2013) Takahisa Furuta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The effects of varying acidity onHelicobacter pylorigrowth and the bactericidal efficacy of ampicillin

(2012) E. A. Marcus et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

(2012) A. G. McNicholl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States

(2010) David Y. Graham et al.   JOURNAL OF GASTROENTEROLOGY

New concepts of resistance in the treatment of Helicobacter pylori infections

(2008) David Y Graham et al.   Nature clinical practice. Gastroenterology & hepatology